Form 4: Cartesian Therapeutics CMO Sells Shares for Tax
Insider Transaction Report
Cartesian Therapeutics' Chief Medical Officer, Milos Miljkovic, sold 3,573 shares of common stock to cover tax obligations and broker fees.
Summary
- Milos Miljkovic, Chief Medical Officer of Cartesian Therapeutics, Inc. (RNAC), reported a sale of common stock.
- The transaction involved 3,573 shares sold at a price of $6.8197 per share.
- The sale occurred on January 6, 2026.
- The purpose of the sale was to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
- Following this transaction, Milos Miljkovic beneficially owns 58,820 shares of common stock directly.
- The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was pre-planned.
Sentiment
Score: 5
Explanation: The transaction is a routine, pre-planned sale by an insider to cover tax obligations and broker fees upon RSU vesting, indicating no specific positive or negative sentiment regarding the company's future prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This insider transaction report is specific to an individual's stock activity and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- Minimal direct impact on shareholders as this is a routine, pre-planned sale for tax purposes, not a discretionary sale indicating a change in confidence.
Key Dates
| Date | Description |
|---|---|
| 01/06/2026 | Transaction Date: Sale of 3,573 shares of common stock by Milos Miljkovic. |
| 01/08/2026 | Filing Date: Form 4 signed and filed by Matthew Bartholomae, Attorney-in-Fact for Milos Miljkovic. |
Recommendation
holdThe reported transaction is a routine, pre-planned sale by an insider to cover tax obligations and broker fees upon the vesting of restricted stock units. It does not reflect a discretionary decision based on new information about the company's performance or outlook, and therefore, does not warrant a change in investment recommendation based solely on this filing.
Keywords
Cartesian Therapeutics, RNAC, Form 4, Insider Transaction, Stock Sale, Chief Medical Officer, Milos Miljkovic, Restricted Stock Units, Tax Obligations, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.